Corcept Therapeutics Inc (NASDAQ: CORT) kicked off on Monday, up 1.61% from the previous trading day, before settling in for the closing price of $72.77. Over the past 52 weeks, CORT has traded in a range of $23.02-$117.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 17.73%. While this was happening, its average annual earnings per share was recorded 27.03%. With a float of $93.22 million, this company’s outstanding shares have now reached $105.11 million.
The extent of productivity of a business whose workforce counts for 500 workers is very important to gauge. In terms of profitability, gross margin is 98.39%, operating margin of 20.29%, and the pretax margin is 23.92%.
Corcept Therapeutics Inc (CORT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Corcept Therapeutics Inc is 11.64%, while institutional ownership is 79.39%. The most recent insider transaction that took place on May 02 ’25, was worth 1,917,951. In this transaction an insider of this company sold 26,554 shares at a rate of $72.23, taking the stock ownership to the 85,622 shares. Before that another transaction happened on May 01 ’25, when Company’s insider sold 12,856 for $71.94, making the entire transaction worth $924,818. This insider now owns 85,622 shares in total.
Corcept Therapeutics Inc (CORT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 27.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 70.50% during the next five years compared to 9.89% growth over the previous five years of trading.
Corcept Therapeutics Inc (NASDAQ: CORT) Trading Performance Indicators
Take a look at Corcept Therapeutics Inc’s (CORT) current performance indicators. Last quarter, stock had a quick ratio of 3.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.62. Likewise, its price to free cash flow for the trailing twelve months is 40.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.23, a number that is poised to hit 0.34 in the next quarter and is forecasted to reach 2.82 in one year’s time.
Technical Analysis of Corcept Therapeutics Inc (CORT)
The latest stats from [Corcept Therapeutics Inc, CORT] show that its last 5-days average volume of 1.22 million was inferior to 1.42 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 73.99%. Additionally, its Average True Range was 5.07.
During the past 100 days, Corcept Therapeutics Inc’s (CORT) raw stochastic average was set at 36.50%, which indicates a significant decrease from 84.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.91% in the past 14 days, which was lower than the 134.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $65.53, while its 200-day Moving Average is $53.13. Now, the first resistance to watch is $75.05. This is followed by the second major resistance level at $76.17. The third major resistance level sits at $78.03. If the price goes on to break the first support level at $72.07, it is likely to go to the next support level at $70.21. Assuming the price breaks the second support level, the third support level stands at $69.09.
Corcept Therapeutics Inc (NASDAQ: CORT) Key Stats
The company with the Market Capitalisation of 7.84 billion has total of 106,045K Shares Outstanding. Its annual sales at the moment are 675,040 K in contrast with the sum of 141,210 K annual income. Company’s last quarter sales were recorded 181,890 K and last quarter income was 30,750 K.
